For decades, evaluation cholesterol risk is built on a simple idea: Reduce “bad” cholesterol, reduce your chances of a heart attack. The test in the middle of the procedure measures how much low-density lipoprotein, or LDL cholesterol, is circulating in the bloodstream. It has created everything from clinical guidelines to the widespread use of statins, LDL-lowering drugs.
It works. Lowering LDL cholesterol reduces heart attack, stroke, and premature death. But it doesn’t tell the whole story.
An LDL cholesterol test measures the amount of cholesterol in low-density lipoprotein particles that circulate in the bloodstream. Those LDL particles that contain cholesterol can get stuck in artery walls, forming plaques that can eventually block blood flow. As the test measures the amount of cholesterol carried, not the number of LDL particles themselves, two people can have the same level of LDL cholesterol but very different numbers of particles, and therefore different levels of risk.
That gap has pushed researchers toward a different way of measuring risk. Apolipoprotein B, or apoB, reflects the total number of cholesterol-carrying cells in the blood rather than the amount of cholesterol it contains. Growing research suggests it’s a more accurate way to identify who is at risk and who isn’t.
In March 2026, the American Heart Association and the American College of Cardiology found this out. Their updated cholesterol guidelines accepted apoB as a potentially more accurate marker, in line with previous European recommendations. But they stopped short of recommending apoB as the primary test method.
“They’re going through the evidence and putting apoB as good, but the real rules of the road continue to prioritize LDL,” says Allan Sniderman, a cardiologist at McGill University.
Sniderman was a writer on a 2026 JAMA modeling study that analyzed lifetime outcomes in approximately 250,000 US adults eligible for statin therapy. Comparing LDL cholesterol, non-HDL cholesterol, and apoB, the study found that using apoB to guide treatment decisions would prevent more heart attacks and strokes than current methods, while remaining cost-effective.
ApoB testing can be done through routine blood tests. So why isn’t it filtered into routine care? Not even in Europe, where the guidelines have demonstrated their usefulness for years.
Part of the answer is circumstance. For decades, LDL cholesterol has been a scientific breakthrough and a public health success story. It’s simple, very understandable, and directly related to treatments that work.
“For 50 years, LDL cholesterol was a surprising discovery,” Sniderman says. “It’s not that it’s not a good score. It’s a good score.”
Børge Nordestgaard, president of the European Atherosclerosis Society, agrees that LDL cholesterol remains central to the cause. “The evidence is overwhelming; it’s beyond discussion,” he says. “Statins reduce heart attack, stroke, and premature death by lowering LDL cholesterol.”
That success helped create a powerful narrative: LDL is “bad cholesterol,” and lowering it saves lives. But that modesty has also reduced how dangerous it is understood.
“The result is patients and doctors know little or nothing about apoB,” Sniderman says.
Recent research shows that the cholesterol picture is more complicated, especially for people who are already taking statins. Previous studies led by Nordestgaard have shown that in treated patients, high levels of apolipoprotein B and non-HDL cholesterol remain associated with risk of heart attack and death, while LDL cholesterol is not. ApoB, in particular, emerged as the most accurate marker.
For Kausik Ray, a cardiologist at Imperial College London, the challenge is not to choose one score over another, but to understand what each one captures, and what it misses.
“We don’t like cholesterol for its own sake,” Ray says. “We’re trying to prevent heart attacks and strokes.”
